Nassim Usman
CIK 1206872 · View on SEC EDGAR ↗
First SEC filing: Jan. 16, 2018 · Latest: Jan. 16, 2018
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 28, 2024 | GYRE | S 10b5-1 | 3,452 | $12.00 | $41,424 | 1,636 Direct | -67.85% | Disposed | -41.8% (price as of 2026-08-20) |
| May 1, 2024 | GYRE | S 10b5-1 | 100 | $15.63 | $1,563 | 1,636 Direct | -5.76% | Disposed | -55.3% (price as of 2026-08-20) |
| May 1, 2024 | GYRE | S 10b5-1 | 5,000 | $14.90 | $74,500 | 1,736 Direct | -74.23% | Disposed | -53.1% (price as of 2026-08-20) |
| May 1, 2024 | GYRE | S 10b5-1 | 14,900 | $13.86 | $206,514 | 6,736 Direct | -68.87% | Disposed | -49.6% (price as of 2026-08-20) |
| April 1, 2024 | GYRE | S 10b5-1 | 20,000 | $16.15 | $323,000 | 1,636 Direct | -92.44% | Disposed | -56.7% (price as of 2026-08-20) |
| March 15, 2024 | GYRE | S 10b5-1 | 20,000 | $17.26 | $345,200 | 1,636 Direct | -92.44% | Disposed | -59.5% (price as of 2026-08-20) |
| Aug. 9, 2022 | GYRE | P | 3,250 | $0.47 | $1,528 | 24,541 Direct | +15.26% | Acquired | -0.9% (price as of 2026-08-20) |
| Feb. 9, 2022 | GYRE | P | 3,250 | $0.46 | $1,495 | 21,291 Direct | +18.01% | Acquired | 1.3% (price as of 2026-08-20) |
| Aug. 9, 2021 | GYRE | P | 867 | $3.62 | $3,139 | 18,041 Direct | +5.05% | Acquired | -87.1% (price as of 2026-08-20) |
| Feb. 9, 2021 | GYRE | P | 582 | $4.81 | $2,799 | 12,174 Direct | +5.02% | Acquired | -90.3% (price as of 2026-08-20) |
| Aug. 10, 2020 | GYRE | P | 582 | $4.81 | $2,799 | 11,592 Direct | +5.29% | Acquired | -90.3% (price as of 2026-08-20) |
| March 13, 2020 | GYRE | P | 4,000 | $3.91 | $15,640 | 11,010 Direct | +57.06% | Acquired | -88.1% (price as of 2026-08-20) |
| Dec. 17, 2015 | GYRE | P | 4,000 | $2.00 | $8,000 | 78,375 Indirect | +5.38% | Acquired | -98.4% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 28, 2024 | GYRE | Stock Option (Right to Buy) | Common Stock (3,452) | $6.93 | Oct. 31, 2033 | 3,452 | Disposed |
| May 1, 2024 | GYRE | Stock Option (Right to Buy) | Common Stock (20,000) | $6.93 | Oct. 31, 2033 | 20,000 | Disposed |
| April 1, 2024 | GYRE | Stock Option (Right to Buy) | Common Stock (20,000) | $6.93 | Oct. 31, 2033 | 20,000 | Disposed |
| March 15, 2024 | GYRE | Stock Option (Right to Buy) | Common Stock (20,000) | $6.93 | Oct. 31, 2033 | 20,000 | Disposed |
| Oct. 31, 2023 | GYRE | Stock Option (Right to Buy) | Common Stock (1,866) | $6.93 | Oct. 31, 2033 | 1,866 | Acquired |
| Oct. 31, 2023 | GYRE | Stock Option (Right to Buy) | Common Stock (341,652) | $6.93 | Oct. 31, 2033 | 341,652 | Acquired |
| April 5, 2021 | GYRE | Stock Option (Right to Buy) | Common Stock (5,000) | $4.63 | July 11, 2027 | 5,000 | Disposed |
| Feb. 8, 2021 | GYRE | Stock Option (Right to Buy) | Common Stock (140,000) | $5.89 | Feb. 8, 2031 | 140,000 | Acquired |
| Feb. 8, 2021 | GYRE | Stock Option (Right to Buy) | Common Stock (140,000) | $5.89 | Feb. 8, 2031 | 140,000 | Acquired |
| Jan. 23, 2020 | GYRE | Stock Option (Right to Buy) | Common Stock (115,000) | $6.85 | Jan. 23, 2030 | 115,000 | Acquired |
| May 20, 2019 | GYRE | Stock Option (Right to Buy) | Common Stock (4,400) | $4.63 | July 11, 2027 | 4,400 | Disposed |
| Jan. 31, 2019 | GYRE | Stock Option (Right to Buy) | Common Stock (5,729) | $4.63 | July 11, 2027 | 5,729 | Disposed |
| Jan. 24, 2019 | GYRE | Stock Option (Right to Buy) | Common Stock (80,000) | $7.97 | Jan. 24, 2029 | 80,000 | Acquired |
| July 30, 2018 | GYRE | Stock Option (Right to Buy) | Common Stock (75,000) | $9.68 | July 30, 2028 | 75,000 | Acquired |
| April 4, 2018 | GYRE | Stock Option (Right to Buy) | Common Stock (88) | $4.63 | July 11, 2027 | 88 | Disposed |
| Jan. 12, 2018 | GYRE | Stock Option(Right to Buy) | Common Stock (95,000) | $15.13 | Jan. 12, 2028 | 95,000 | Acquired |
| July 11, 2017 | GYRE | Stock Option (Right to Buy) | Common Stock (275,000) | $4.63 | July 11, 2027 | 275,000 | Acquired |
| June 9, 2016 | GYRE | Stock Option (Right to Buy) | Common Stock (0) | — | — | 0 | Acquired |
| June 9, 2016 | GYRE | Stock Option (Right to Buy) | Common Stock (7,500) | $1.88 | June 9, 2026 | 7,500 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock (153,572) | $4.40 | Oct. 22, 2025 | 153,572 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock (71,428) | $4.40 | Oct. 22, 2025 | 71,428 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock (153,572) | $4.40 | Oct. 22, 2025 | 153,572 | Acquired |
| Aug. 20, 2015 | GYRE | Warrant (Right to Buy) | Common Stock (29) | $33.27 | April 9, 2019 | 29 | Acquired |
| Aug. 20, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock (22,508) | $11.52 | Jan. 2, 2023 | 22,508 | Acquired |
| Aug. 20, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock (61,118) | $7.33 | March 16, 2019 | 61,118 | Acquired |
| Aug. 20, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock (8,786) | $9.43 | April 9, 2018 | 8,786 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GYRE
President & CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2020 | $574,244 | — | — | — | $178,750 | — | $16,191 | $1,409,622 |
| 2019 | $524,832 | — | — | — | $211,560 | — | $7,109 | $1,198,865 |
| 2018 | $480,800 | $240,400 | — | — | — | — | $5,372 | $2,442,313 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.